Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Alnylam, Dicerna tussle over RNAi tech

In June, Alnylam Pharmaceuticals sued Dicerna Pharmaceuticals in the Superior Court of Middlesex County, Massachusetts, for misappropriation of trade secrets relating to the N-acetylgalactosamine conjugate technology for delivering RNA therapeutics. The dispute between the Cambridge, Massachusetts–based companies stems from Alnylam's $175-million purchase of Sirna Therapeutics from Merck, of Kenilworth, New Jersey, in 2014. Alnylam claims that after the acquisition, Dicerna hired several laid-off Merck researchers who “collected and took to Dicerna proprietary materials and confidential trade secret information relating to Sirna's siRNA delivery technologies,” which rightfully belonged to Alnylam in accordance with its asset acquisition. Dicerna has denied the claims, calling many of the insinuations in the Alnylam complaint simply false and others, unfounded speculation. “Our RNAi-based therapeutics utilize our proprietary RNAi [RNA interference] technologies, and not prior Merck research. We stand behind these technologies, and the company's record and practices for respecting IP [intellectual property] rights, in order to develop and deliver life-changing therapies as efficiently as possible,” said Dicerna CEO Douglas Fambrough in a statement. Given the different nature of trade secrets compared with patents, and what “reasonable protective measures” Alnylam took as the trade secret holder, industry watchers expect the companies to settle before the court reaches its decision.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alnylam, Dicerna tussle over RNAi tech. Nat Biotechnol 33, 791 (2015).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing